Trial Profile
Phase I trial of complement C1 inhibitor protein (C1-INH)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2020
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions
- Sponsors Liminal BioSciences
- 12 May 2015 New trial record
- 07 May 2015 ProMetic intends developing complement C1 inhibitor protein (C1-INH) for the treatment of hereditary angioedema and anticipates commencing this trial in the first half of 2016, according to a media release.